Description

The CJC-1295 (without DAC) and Ipamorelin combination is a high-purity synthetic peptide blend designed to investigate the maximal synergistic potential of the Growth Hormone (GH) axis. In advanced endocrine research, this dual-action formulation is considered the gold standard for simulating natural, pulsatile GH secretion.

CJC-1295 (No DAC): A tetrasubstituted 29-amino acid analog of GHRH (Growth Hormone Releasing Hormone). It functions by binding to GHRH receptors in the anterior pituitary, increasing the total amount of GH secreted per pulse.
Ipamorelin (IPA): A selective pentapeptide and Ghrelin receptor agonist. It acts by triggering a specific GH pulse while simultaneously inhibiting Somatostatin (the hormone that blocks GH release).

By utilizing this 5mg+5mg blend, researchers can explore the amplified bio-response that occurs when GHRH and GHRP signaling pathways are activated simultaneously. Unlike single-peptide models, this synergy produces a far more potent physiological effect on IGF-1 upregulation, protein synthesis, and cellular repair, all while maintaining high receptor sensitivity.